-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WsHookj2KeFoN3Dq1+LM8Uw5AYIEWGw3bRnMeMPFkdOTYEoviLI30Zot9NzmYFcA
 Vj+8O1liuux6TQNJe+5Tkg==

<SEC-DOCUMENT>0001075880-08-000028.txt : 20080325
<SEC-HEADER>0001075880-08-000028.hdr.sgml : 20080325
<ACCEPTANCE-DATETIME>20080325081421
ACCESSION NUMBER:		0001075880-08-000028
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080325
FILED AS OF DATE:		20080325
DATE AS OF CHANGE:		20080325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		08708267

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k200803253.htm
<DESCRIPTION>FORM 6K 2008 03 25 3
<TEXT>
<html>
  <head>
    <title>form6k200803253.htm</title>
<!-- Licensed to: Novogen Laboratories Pty Ltd-->
<!-- Document Created using EDGARizer 4.0.5.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 5%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5%; FONT-FAMILY: Times New Roman">
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">______________________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For the
month of March, 2008</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140 Wicks
Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(Address
of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form 20-F
<font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf </font>by the undersigned, thereunto duly
authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Ron
Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Date
25 March, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right"><img src="novogenletterhead.jpg" alt="Novogen logo"></div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">ASX
&amp; MEDIA RELEASE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">25
MARCH, 2008</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">DATA
TO BE PRESENTED AT AACR REVEALS THAT THE MARSHALL EDWARDS&#8217; COMPOUND TRIPHENDIOL
MAY AID IN TREATMENT OF PANCREATIC CANCER</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited&#8217;s subsidiary, Marshall Edwards Inc., (NASDAQ: MSHL), has made the
following announcement:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">New
Canaan, CT, March 25, 2008 - Marshall Edwards, Inc., (Nasdaq:
MSHL).&#160;&#160;The abstract for a &#8220;late breaking&#8221; presentation at the Annual
Meeting of the American Association for Cancer Research, April 12-16, San Diego,
Calif., is now available at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.aacr.org</font>
(abstract# 8989).&#160;&#160;The abstract is titled &#8220;Triphendiol (NV-196)
induces apoptosis and sensitizes pancreatic cancer cells to
gemcitabine.&#8221;&#160;&#160;Triphendiol was recently granted orphan drug status by
the U.S. Food and Drug Administration (FDA).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">There is
an urgent need for new pancreatic cancer treatments because fewer than 20
percent of patients are candidates for surgery
(pancreotectomy).&#160;&#160;Current treatment is limited to chemotherapy with
gemcitabine, to which most patients are resistant or acquire
resistance.&#160;&#160;This study assessed the potential of triphendiol as a
treatment for pancreatic adenocarcinoma using three representative cell
lines.&#160;&#160;Triphendiol induced apoptosis (cell death) in all cell lines
and pre-treatment with triphendiol increased gemcitabine-dependent
apoptosis.&#160;&#160;Animal model studies showed that triphendiol in
combination with gemcitabine inhibits tumor growth more effectively than each
drug alone. Both triphendiol and gemcitabine induce apoptosis via a
mitochondrial pathway.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Laboratory
testing <font style="DISPLAY: inline; FONT-STYLE: italic">in vitro</font> and in
animals bearing human pancreatic and bile duct tumors has demonstrated the
activity of triphendiol against cancer cells. In mice bearing a human pancreatic
cancer tumor, triphendiol administration resulted in a mean reduction in tumor
volume by 62 percent compared with untreated control animals.&#160;&#160;In the
two Phase I clinical studies completed thus far, the investigational drug has
demonstrated acceptable pharmacokinetic profiles in human volunteers with no
reported side effects.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Professor
Alan Husband, Group Director of Research for Marshall Edwards, says,
"This&#160;&#160;study being presented at AACR is an important step in the
clinical development program for triphendiol as a safer multipotent anti-cancer
agent.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">"We
continue to see evidence that triphendiol will be of benefit in unusually
aggressive and difficult-to-treat diseases such as pancreatic cancer," Professor
Husband said.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Pancreatic
cancer is considered an "orphan" cancer, because of its relatively low incidence
and high mortality.&#160;&#160;It is slightly more common in men than in women.
In the U.S., it is the fourth leading cause of cancer-related death in men and
the fifth leading cause of cancer-related deaths in women with a death rate
estimated by the National Cancer Institute of approximately 96 percent of
patients with the disease<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font>.&#160;&#160;The
American Cancer Society estimated the number of new cases of pancreatic cancer
in the U.S. in 2007 as 37,170, with 18,830 cases diagnosed in men and 18,340 in
women<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font>.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Pancreatic
cancer has a poor prognosis.&#160;&#160;The disease is difficult to diagnose in
its early stage, and patients usually present with incurable disease. It has a
high mortality rate, and no therapy has been shown to significantly impact
survival.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Triphendiol</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Triphendiol
(NV-196) is another investigational drug in the Marshall Edwards, Inc., oncology
drug pipeline, currently being developed as an orally-delivered chemosensitizing
agent, intended for use in conjunction with standard chemotoxic anti-cancer
drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma, and
melanoma. Triphendiol is broadly cytostatic and cytotoxic against most forms of
human cancer cells in vitro, and has been shown to cause cell cycle arrest (or
stop cells increasing in number) and to induce apoptosis (or initiate programmed
cell death) in various cancer cell lines.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Biological
studies suggest a mechanism of cytotoxicity that involves mitochondrial
depolarization and downregulation of XIAP.&#160;&#160;It exhibits high
selectivity, little effect on non-tumor cells and no observable toxicity in
animals at therapeutically effective doses. In human studies conducted so far,
no adverse events or side effects have been reported when administered to
volunteers.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Marshall Edwards, Inc. and Novogen Limited</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
Edwards, Inc., is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics.&#160;&#160;These derive from a
flavonoid technology platform that has generated a number of novel compounds
characterized by broad ranging activity in laboratory testing against a range of
cancer targets with few side effects.&#160;&#160;The ability of these compounds
to target an enzyme present on the surface of cancer cells, and inhibit the
production of pro-survival proteins within the cancer cell suggests that they
may possess a unique combination of efficacy and safety. Marshall Edwards, Inc.
has licensed rights from <font style="DISPLAY: inline; FONT-WEIGHT: bold">Novogen Limited</font> (ASX: NRT;
NASDAQ: NVGN) to bring three oncology drugs - phenoxodiol, triphendiol (NV-196)
and NV-143 - to market globally.&#160;&#160;Marshall Edwards, Inc., is majority
owned by Novogen, an Australian biotechnology company that is specializing in
the development of therapeutics based on a flavonoid technology
platform.&#160;&#160;Novogen, based in Sydney, Australia, is developing a range
of therapeutics across the fields of oncology, cardiovascular disease and
inflammatory diseases. More information on phenoxodiol and on the Novogen group
of companies can be found at www.marshalledwardsinc.com and
www.novogen.com.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Under
US law, a new drug cannot be marketed until it has been investigated in clinical
trials and approved by the FDA as being safe and effective for the intended
use.&#160;&#160;Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995.&#160;&#160;You should be aware that our actual results could differ
materially from those contained in the forward-looking statements, which are
based on management's current expectations and are subject to a number of risks
and uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development and/or
FDA approval, or the failure to obtain such approval, of our product candidates;
uncertainties in clinical trial results; our inability to maintain or enter
into, and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products;
competitive factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual property to
operate our business; our inability to operate our business without infringing
the patents and proprietary rights of others; general economic conditions; the
failure of any products to gain market acceptance; our inability to obtain any
additional required financing; technological changes; government regulation;
changes in industry practice; and one-time events.&#160;&#160;We do not intend
to update any of these factors or to publicly announce the results of any
revisions to these forward-looking statements.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font>&#160;&#160;National
Cancer Institute, A Snapshot of Pancreatic Cancer</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(available
at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.orpha.net/data/patho/Pro/en/MelanomaFamilial-FRenPro3560.pdf</font>)
..</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">2</font>&#160;&#160;Cancer
Facts and Figures, American Cancer Society, 2007.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">3</font>&#160;&#160;Cancer
Facts and Figures, American Cancer Society,
2007.</font></div>
    </div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenletterhead.jpg
<DESCRIPTION>NOVOGEN LOGO
<TEXT>
begin 644 novogenletterhead.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!E`/P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`JM!<QRW=U`I^>%EW#ZJ"*LUYWJ?B>/PW\6UM[QQ'8ZE8PH
M[MP$D#N$8GTY(/U!/2FE<SJ34+-GHE%%%(T"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHK.UG7-/T"S6[U*8PP,XC#!"WS$$@8
M`/H:&[;CC%R=HJ[-&BL_1]<T[7[,W>FW`GA5RC':5(8=B#SW'YUH4)WV"47%
MVDK,**R;KQ)I=EKEOHT]P5OK@`QQ^6QR#G'.,=C6M233'*$HV;6X457O;ZUT
MZU>YO;B*W@3[TDC!0/SKDI_BIX7AE*+/<2C^\D#8_7%)RBMV73H5:GP1;.UK
MQ'XX6I77-*NC]V6V:/\`[Y;/_L]>I:+XOT/Q`_E6%\C3XSY,@*/^`/7\,UQW
MQKTXW'AJROU4DVESM8^BN,']0M:4I+F31QX^E*-*49*S10^&'Q#\[R/#VLS?
MO>$L[AS]_P!(V/KZ'OTZXSZY7Q_].#7T)\,?&;>)=(:QOI-VIV:@.Q/,T?0/
M]>Q]\'O6E6%M4<N"Q/-^[GOT.\HHK+UOQ%I?AV"*;5+GR4E8JF$9B3C/0`U@
MVEJSTXQE-\L5=FI138W$D:N`0&`(##!_$=JY_6/''A[0YF@N[]6N%.&BA4R,
MOUQP/H:&TM6.%.<WRP5V=%17&6OQ2\+W,H1KF>#)QNEA('YC.*Z^WN(;J!)[
M>:.:%QE)(V#*P]B*2DGLRJE&I3^.+1)114%Y>VNGVS7-Y<16\"?>DE8*!^)J
MC-)MV1/17%W'Q2\+P2%%N9Y@#C='`V/UQ5O3_B)X8U&80IJ(AD8X`N$,8/XG
MC]:CVD>YN\)72NX/[CJ:**YS4_'7A[1]1FL+V]:.YAQO40NV,@$<@8Z$53:6
MYE"G.H[05WY'1T5R/_"S/"G_`$$7_P#`>3_XFMO1/$&F^(;>6?3)S-'$^QR4
M9<'`/<#L:2G%Z)ESP]6"YI1:7H:=%8>M^+M%\/7,=OJ=TT,LB>8H$3-D9QV!
M]*U[:YAO+6*YMY%D@E0/&Z]&4C(-.Z;L0Z<XQ4FM&2T45D:9XGTG5]2NM/LK
MDR7-J6$J&-EVX;:>2,'FBZ0E"4DVEL:]%%%,D*X'XN_\BA!_U^I_Z"]=]7`_
M%W_D4(/^OU/_`$%ZBK\#.O`_[S#U.1\-7T_@37=.DN7/]D:Q:0RL[=%W*#GZ
MJQ(/^R<^E>V=1D5PUQX:3Q/\+]*M5"B[CL89+9SV<1CC/H1P?S[5'\,_$KZA
MIKZ)?%EO]/&T!^&:,''/NI^4_A44_=?+T9T8M*O%UE\479_HS,\3?\EGT'_K
ME%_Z%)7ILLJ00O+*P2-%+,QZ`#DFO,O$W_)9]!_ZY1?^A25UOCV=[?P-JSH2
M"8?+X]&8*?T)IQ=N9DUX<_L8=TE^)YU;QW_Q4\5R/-+)!H]H<A1_`AZ`#IO;
M!))Z<^@%>G67A'P_I]L((-(M"H')DB$C-]6;)-8'PHMHX?!@F4#?<7$CN?H=
MH_1:[FBG%6YGNQ8VO)5'2AI&.ECS3QI\.[9+1]7\/Q&UN[;]ZT$1(#`<Y3^Z
MPZC'7ZU/H.I'XA^`-2TF\93J"1>4SG@,>L<GYKS[J?6O1*\D\`QC3OB=K>GP
M\0!9U`]`L@V_D"12:Y)IKJ.,OK.&G"IJXZI^75'CDL4D$KPS(4EC8HZ,,%6!
MP0?QK6\+:[)X;\266IH3LC?$RC^*,\,/RY'N!7<?%WP>]CJ!\1646;2Y(%T%
M'^KEZ!OHW\_K7E]>DFI(^,J0E0J6['U\CK)&LB,&1@"K`\$'O7F'B,?\)5\5
M=.T8?/::<`\P[9X=OSPBUN^`M>CE^&=K?W3Y%A`\<I]!%D#_`,="UE_"NSEO
M&U;Q+=C]_>SLBGVSN?'MD@?\!KSZJ]Y0/K<#*U*6(\K+U?\`DBS\3/%EQH]I
M#I.G.R7UXN6=/O1QYQ\O^TQR`?8]\&E\(_#73]-LX[G6+>.[U!QN9)/FCB]@
M.A/J3GGI6%?QC4?CM!!/S'"Z%1_N0^8/_'J];J8KGDY/H;UIO#T84J>G,KM^
MI@ZGX+\/:K;&&;2[>,X^62!!&Z^X(_D<BO.=+N[_`.&OC$:3>3F72;E@=Q^[
MM8X$@'8@C##T'T->R5YI\9+6-]&TVZ(_>)<-$#_LLI)_]!%%6-ES+="P-9SG
M["H[QE^'FCT>XN(K6VEN)W"11(7=CV4#)/Y5X_8VVH?%3Q'+=7LLEOHUHV%C
M0_=!Z*.V\CDMV_*NI\57\Q^$0N"Q,MQ:6X=NA.\H&_/)_.KGPRMH[?P)9.@&
MZ=Y)7/J=Y'\E`_"B7OR4>FXZ/^ST)55\5^5>7<U+/P?X=L81'#HUF0!C=)$)
M&/U+9)JI?_#_`,,Z@Z.VF1P.KALV_P"[#8.<$#@@]#Q^5=-2,RK]Y@/J:TY(
M[6.-8BJGS*3OZB@8&!TKRAK&TU'XX7UM>VT5Q`8P3'*H921"F.#7J]>-:QK+
MZ#\8-0OX[*2\9451#&<$YA3GH>GTJ*ME:_<ZLO4I2J*._*_T/2O^$/\`#?\`
MT`M/_P#`=?\`"M#3]+L-*B>/3[."U1VW,L*!03C&3BN!_P"%J7G_`$*=]_WV
MW_Q%>@:==&^TRTO&B:%IX4E,3=4+`'!^F<547!_"8UZ>(IK][L_._P"IY?\`
M$NS74?'>A6+N46YC2(N!DJ&D(S^M7/ASK%QI&IW7@[53LF@=C;9[]V4>Q'SC
MV)]JC\=_\E-\,?[T/_HZKOQ-\/RM##XFTW,=]8$&5DZE`<AOJI_0GTK&S4G)
M=#T5*,Z-.A/:2T\G?0]$KRKX=?\`)0O$G^]-_P"CC7=^%?$$/B708+^/"R_<
MGC'\$@ZCZ=Q[$5PGPZ_Y*%XD_P!Z;_T<:N33<6CEH0E"E6C+=)?F>JT445L>
M<%<#\7?^10@_Z_4_]!>N^KC?B9I5_J_AF&WT^UDN9A=HY1,9"A6&>?J*BI\+
M.K!-1Q$&^YM>$_\`D3]%_P"O&'_T`5PGCW3+GPQXCM?&&E)\ID`N4'`W].?9
MAP??!ZFO0/#EO-:>&-*MKB,QS16D22(W56"`$5:U&PM]4TZ>QNTWP3H4<>Q[
MCW'44G'FC8JG7]E7<MT[W\T>6ZEJ5OJ_Q3\,ZA:-N@N+>)USU'S29!]P<@_2
MO1_$>FMK'AS4-/3_`%D\#*G./FQE?U`KR30_">M:/\0+&.:QNI;:UNL"Z6)C
M&4P2&ST'7\#FO;ZFE=IW-\<XTY4_9N]EI]YYC\(];3[)=:#<-LN(I#-$C<$J
M<!E^H(S^/M7IU>>>+_A_<W6I_P!N^')A;ZB&\QXMVS>W]Y3V8]P>#[<YI1>-
MO&^GH;>_\*RW,ZC`E2%P"?4[05/X8HC)P7+(*U&.*E[6BU=[INS3/1-5U.VT
M?2[C4+MML,"%F]3Z`>Y.`/K7FOPHM+B_UG5_$-PN/,)C!QP7=M[X^GR_G44N
MA^,_'MU$VLK_`&9IR-N$97;CW"$Y+>[8QSCTKT[2=*M-%TR#3[*/9!"N!DY)
M/<D]R3S0KSDGT1,N3#494T[SEO;HB>ZM8+ZTEM;J))8)5*21N,A@>H-?.WCW
MP)<>$;[SH-TNDSMB&4\F,_W&]_0]_P`Z^CZJZCIUKJVG3V%[$LMM.A1T/IZ^
MQ'4'L173";BSQL1AXUHVZGSYHFOO;_#S4="B.9[N_3:@/)0J,X_%%'_`C7O7
MA[2ET3P_8Z:N"8(@KD?Q/U8_B237D7A'P+>:?\3'LKJ&5K/3W^T+.4(64#F/
MGIG)4D>Q%>X5$E^\<CJHSM@J=+KJWZW:7X(\B\=>;X:^)&G^(0C&"78[%>Y4
M;'7Z[,?G7K%M<0WEM%<V\BR0RJ'1UZ,IY!K/\0Z!9^)-)DL+P$`G='(OWHW'
M1A_GD$UYS:6GCKP$SV]G:C5=-W$JJ*9`,]PH.Y3ZCD?7K6.L)-]&>A[N*I1C
M=*<=->J/6Z\D^*>I'6-:T_PW8'S9D<%P#QYK\*OX`DG_`'JLW/B[QWK*&UTS
MPW-8LXP9GC;(^C.%4?CFMCP3X!.A7!U7595N=4?)&"66+=U.3RS')R?<_4DF
MZGNQV*HTXX1^UJM<RV2=]?,V]>T#[;X)N-$M^66V6.'/=D`*_JHKD_A-K\3Z
M=+H$[;+F!VDA5N"R$Y8?4-G/U]C7I=>>>+_AY+?:@=;\/S_9M1W>8\>[8';^
M\K#[K?H?;G+G%IJ43+#U83A*A5=D]4^S/0Z\T^,P!T/3<_\`/RW_`*`:JP>+
M_'VD@6VH>'9+QDX\P6[Y;_@294_@*S]=_P"$T\>106TGATVD,,A=2ZM%R1CD
MN1D8]!4SFI1:2U-\+A94:T:DY+E76Z/7K/\`X\;?_KFO\J\WM/\`DO%[_P!<
MO_:*5Z7;HT5M%&V-RH%./4"O+M9L/$^G_$F^UW2-&:[0JJQL^-C`Q*I_B!Z@
MU539>IA@K.5172O%K7Y'JM%><?\`"3_$3_H5;?\`(_\`Q==+X4U/Q#J*79U_
M2X[`H5\D)_&#G/\`$>G'YU2FF[&-3"RIQYFU\FCD/'?_`"4WPQ_O0_\`HZO3
MW19$9'4,C##*PR"/0UP'C#1-3O\`Q]X?OK2RDFM;=HC+*N,)B7)SSZ<UZ#2@
MO>D:8F2=*DD]E^IY%:._PU\?-:RLPT34>58]$7/!^J$X/^R<^E6/AUQ\0O$O
M^]-_Z.-=EXU\-)XG\/R6R!1>1?O+9SV<?PY]"./R/:N,^%FD:KI^O7\VH:?>
M6RO;X#SQ,H9MP/4]36?*XS2Z'8JT*N&G-OW[)/SMLSU:BBBN@\8****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**IPZI:7-Z;2!Y)7",QD2
M)VB&URC+YH&S>&!!3.X8/%7*`"BBL_1-;T[Q'H\&K:3<?:+&?=Y<NQDW;6*G
MA@".01R*`-"BBB@`HHHH`**IWFJ6EC<6MO,\AGNGVQ1Q1/(QY`+$*"50%E!<
MX5=PR1D5<H`**S]*UO3M;^V_V=<>=]ANY+*X^1EV3)C<O(&<9'(R/>M"@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`KD_'>F:UJMOH<&C27:(NL6[Z@;6[-N
MWV3#"3+!E)'(X!STQTKK**`/"_"WA7XH1WNGCQ%J6LBW#QAO(O5E*PEY1+'*
MWVA,$JX;S%61U&S:5*;:Z#P[H'C>+6-%GU>;4GLYGMWO(GU(YM3;6AC^8*YW
MB:=MY"DC"*7R6(7U2B@#PM[WQ7=?%:;3=/UZ2>[:XU1D:"_$UK!$+=5MEEA4
MD1F.4X;?&,L>KFJ\7A/XH.;5)+WQ!Y0LKEI8VU%8@EU]FVQ[9%NG>0&55/S;
M5!)(50S`>^44`?/DWA7XP_V-,C:EK+:DR(B_9[V/RWCVQ':TC7"E'4HP+)'E
MCNR[A\CL_$FF>-;KQIIL&D65];Z%:2VUO+=IJK$W-L0PG+!IP0P#@!MC2$KN
M$@(45ZA10!\\>'_!/Q*TB/2+6"WU6TTRVB4:E:1:LB_:?]++N(-LN(V,97D&
M/[KC/S?-IZCX5^*D^CVZM?:E)?PZ%'&K6VJ^4/M?VO.&PZAG%N2"QR"1]YC@
MU[I10!XW\19O%=S\26TWPO/J37B:%%=VT%O>"*))5N\-(Z,ZHX*!EP0V=PXP
M,C#T'PC\1?#6GZ=9VVE7TMK+IYANX%UC:EM,;QG,B(MPF6\I5&$=`=YR>6!^
M@**`/"WT#XLR:9:3F;4AJ=IHZ)&%U)`K7:WN1O4/LD/V;J7!#=\M5B]T/XEV
M%^)]/MM2U""&]U*&*VEULHKVCH!;,Y\T,Q5GD8$GS/E`W+A"/;**`/'_``CH
M_P`0K?Q-#+XF35;C1(I9ELX(=15'@)EC9))\3EI(]N\;6DF(P1@C!.7;Z!\5
M;34M.N;F[UF\,6IQS:A#!=0K!<1)*[%HV:X!PRL!Y8CB0C;D97)]THH`^?-+
M\"_$BV\6^$=8G74C+&D4>KW$FK!V*"[=F0YD)9/*\L[5R#Z9S6W=Z5\15\+G
M35TW5;G6YI;A[S5EUG;&6!E\DV\:W$>U3O7(*JH"C,;D`#VBB@#P?3?#'Q'L
M/!L^;*^.NW&MSZA-;PWL4,-P'CC4F5XIHW7YB[*$;&5PRX*D>\444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
5%%`!1110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
